Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics (TARA)
NASDAQ:TARA
TARA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.68 - $10.48
Previous CloseN/A
Volume145.20K
Average Volume (3M)599.74K
Market Cap
$201.40M
Enterprise Value$9.81M
Total Cash (Recent Filing)$122.22M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Oct 30, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding38,581,863
10 Day Avg. Volume673,426
30 Day Avg. Volume599,735
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue29.56
Enterprise Value/Gross Profit-99.12
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$24.20Price Target Upside363.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Competitive EdgeProtara's drug has the best-in-class safety profile, which alongside its alternative biological profile and ease of administration, offers a competitive edge.
Market OpportunityWith three major catalysts in the next 12 months, an undervalued pipeline asset with a large market opportunity, as well as negative news for competitors presenting clear openings for Protara, a BUY rating and $21 PT is initiated.
Regulatory ProgressProtara recently received alignment with the FDA on the registration trial for IV Choline in Parenteral Support patients, demonstrating regulatory progress.
Bears Say
Competitive PressuresAnalyst remains cautiously optimistic with TARA-002 in the high-risk NMIBC setting, even as the competition continues to heat up.
Regulatory ChallengesThe biggest concern noted was that the FDA is unlikely to accept a single-arm registrational trial design for '002 in the BCG-Exposed group.
Safety ConcernsHigh rates of bladder-related toxicity and systemic flu-like symptoms are notable concerns with BCG treatment, impacting its overall safety profile.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics’s price range in the past 12 months?
Protara Therapeutics lowest stock price was $1.68 and its highest was $10.48 in the past 12 months.
What is Protara Therapeutics’s market cap?
Protara Therapeutics’s market cap is $201.40M.
When is Protara Therapeutics’s upcoming earnings report date?
Protara Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 17 days.
How were Protara Therapeutics’s earnings last quarter?
Protara Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.035.
Is Protara Therapeutics overvalued?
According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued.
Does Protara Therapeutics pay dividends?
Protara Therapeutics does not currently pay dividends.
What is Protara Therapeutics’s EPS estimate?
Protara Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Protara Therapeutics have?
Protara Therapeutics has 38,581,863 shares outstanding.
What happened to Protara Therapeutics’s price movement after its last earnings report?
Protara Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went down -0.958%.
Which hedge fund is a major shareholder of Protara Therapeutics?
Currently, no hedge funds are holding shares in TARA
Protara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.20 (363.60% Upside)
$24.20 (363.60% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 23.1%
Last 30 Days ▲ 158.8%
Last 30 Days ▲ 158.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
222.22%
12-Months-Change
Fundamentals
Return on Equity
-43.02%
Trailing 12-Months
Asset Growth
54.39%
Trailing 12-Months
Company Description
Protara Therapeutics
Protara Therapeutics (TARA) is a clinical-stage biopharmaceutical company focused on identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company leverages its deep expertise in clinical development and regulatory strategies to bring innovative therapies to patients with significant unmet medical needs. Protara's core product initiatives include TARA-002, an investigational cell therapy for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a rare pediatric disease product candidate.
TARA Stock 12 Month Forecast
Average Price Target
$24.20
▲(363.60% Upside)
Technical Analysis
Protalix
―
TuHURA Biosciences
―
Skye Bioscience
―
Orchestra BioMed Holdings
―
Zura Bio
―
Ownership Overview
4.11% Insiders
5.32% Mutual Funds
40.16% Other Institutional Investors
43.40% Public Companies and Individual Investors
Options Prices
Currently, No data available
---